Results

Total Results: 1,640 records

Showing results for "therapy".

441. Restless-Legs Executive (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/restless-legs_executive.pdf
     November 01, 2012 - Nonpharmacologic Therapies Four small, short-term studies assessed nonpharmacologic therapies in adults … One low-quality RCT evaluated near-infrared light therapy compared with sham treatment. … However, adverse effects of pharmacologic therapies and long-term treatment withdrawals due to adverse … • Randomized trials of nonpharmacologic treatments including herbal therapy, mind-body medicine, and … characteristics, such as disease duration and previous therapy, affect treatment outcomes

442. Diabetes Mellitus (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/diabetes-horizon-scan-high-impact-1312.pdf
     January 01, 2016 - Many patients with T2DM do not meet treatment goals and require additional therapy with one of two … have additive therapeutic effects and result in better glycemic control. … have additive therapeutic effects and result in better glycemic control. … ., anti-VEGF therapies). … Intarcia Therapeutics. A study to evaluate ITCA 650 for the treatment of type 2 diabetes.

443. Disposition of Comments for CER 161 Major Depressive Disorder (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/major-depressive-disorder-disposition-160504.pdf
     December 08, 2015 - of antidepressant treatments despite the evidence that treatment resistance has a clear impact on … or Psychodynamic Therapies. … John's wort), and availability of clinicians who are well trained in a specific therapeutic option … (with cognitive therapy) versus medication treatment alone (see attached). … therapy, psychodynamic therapy and behavioral activation.

444. Contrast-Induced Nephropathy (CIN): Current State of the Evidence on Contrast Media and Prevention of CIN (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/nephropathy-contrast-induced_clinician.pdf
     August 01, 2016 - of CIN (with IA administration) 18d 4194 ⬌ – 0.80 (0.64 to 1.01) ��� Need for renal replacement therapy … e Renal replacement therapy consisted of hemodialysis or hemofiltration. … g Renal replacement therapy consisted of hemodialysis or hemofiltration. … (in patients receiving the IOCM) 7 1339 ⬌ – 1.12 (0.74 to 1.69) ��� Need for renal replacement therapy … of CIN (in studies using the IOCM) 7 1748 ⬌ – 1.02 (0.70 to 1.48) ��� Need for renal replacement therapy

445. Diabetes Mellitus (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/diabetes-horizon-scan-high-impact-1412.pdf
     January 01, 2015 - therapeutic effects and better glycemic control. … The mode of delivery, an implanted pump, is an established therapy for other drugs or other treatments … Unlike other treatments for T2DM, management of therapy with the ITCA 650 is controlled by the device … , corticosteroids, or anti-VEGF therapies, making this new intervention just another treatment option … Investigational therapeutic options in the management of DME: investigational pharmacologic treatments

446. Binge-Eating Research-Protocol (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/binge-eating_research-protocol.pdf
     July 21, 2014 - Current Treatment Options for BED Current treatments for BED and LOC eating include psychological and … efficacy of pharmacological interventions, efficacy of CAM treatments, treatment efficacy in diverse … and costs-benefit assessments of different treatments, treatment stepped-care models, and treatment … Cognitive-behavioral therapy, behavioral weight loss, and sequential treatment for obese patients with … Cognitive behavioral therapy guided self-help and orlistat for the treatment of binge eating disorder

447. Hypertension-Pulmonary-Arterial Research-Protocol (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/hypertension-pulmonary-arterial_research-protocol.pdf
     January 30, 2013 - Diagnostic thinking efficacy and therapeutic efficacy (clinician judgment about diagnosis/prognosis, … choice of treatment) 2. … currently in use (such as specific components of treatments considered to be supportive therapy), and … 1.5 mg Varies Intravenous (continuous infusion) Approved Remodulin Treprostinil United Therapeutics … ml 5 mg/ml 10 mg/ml Varies Intravenous; Subcutaneous Approved Tyvaso Treprostinil United Therapeutics

448. Diabetes Mellitus (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/diabetes-horizon-scan-high-impact-1406.pdf
     September 26, 2014 - therapeutic effects and better glycemic control. … The mode of delivery, an implanted pump, is an established therapy for other drugs or other treatments … Unlike other treatments for T2DM, management of therapy with the ITCA 650 is controlled by the device … , corticosteroids, or anti-VEGF therapies, making this new intervention just another treatment option … Investigational therapeutic options in the management of DME: investigational pharmacologic treatments

449. Adverse Effects of First-Line Pharmacologic Treatments of Major Depression in Older Adults (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/ehc-depression-research-protocol.pdf
     February 07, 2018 - treatments and will not include nonpharmacologic treatments or complimentary alternative medicines. … treatment. … CBT, interpersonal psychotherapy, problem solving therapy, psychodynamic or supportive therapy, behavioral … Other pharmacologic anti-depressant monotherapy, placebo, or nonpharmacologic therapy Adverse … , non- pharmacologic therapies, complementary alternative medicines, or combinations of therapies

450. #14 SUBSTANCE ABUSE (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/14_substanceabuse_potential_high_impact_june_2012.pdf
     January 01, 2012 - new (and new uses of existing) pharmaceuticals, medical devices, diagnostic tests and procedures, therapeutic … , screening and diagnostics, therapeutics, surgery, programs, and care delivery innovations that address … For this report, topics that emerged as higher impact focused on treatments for opioid and nicotine … — as do current therapies—but that the monthly visit to a provider for the injection represents a small … About buprenorphine therapy. [internet].

451. Effective Health Care (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/TND_0075_03-10-2009.pdf
     January 01, 2009 - The nominator specifically mentions Remicade, Imuran, anti-inflammatories, and biologic therapies for … the treatment and management of Crohn’s disease. … Comparator(s): Comparisons of the above pharmacologic treatments. … What treatments or therapies, alone or in conjunction with one another, provide the highest rate of … , and the person’s response to previous medical treatments.

452. Evidence-based Practice Center Systematic Review Protocol (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/cerebral-palsy-feeding_research-protocol.pdf
     June 12, 2012 - intake), and concurrent medications that potentially have gastrointestinal side effects may influence treatment … www.effectivehealthcare.ahrq.gov/ Source: www.effectivehealthcare.ahrq.gov Published Online: June 12, 2012 treatment … Practice parameter: pharmacologic treatment of spasticity in children and adolescents with cerebral … "[mesh] OR "occupational therapy"[tiab] OR "Behavior Therapy"[mesh] OR "behavior therapy"[mesh] OR … " OR KW="Behavioral Therapy" OR KW="Behavior Therapy" OR KW="Behavior Modification" OR KW="Behavior"

453. PULMONARY with "Discussions" in Exec Summary (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pulmonary-horizon-scan-high-impact-1412.pdf
     October 01, 2015 - new (and new uses of existing) pharmaceuticals, medical devices, diagnostic tests and procedures, therapeutic … , screening and diagnostics, therapeutics, surgery, programs, and care delivery innovations that address … Therapies targeting CFTR mutations have been proposed to treat CF; however, therapies targeting molecular … Additionally, 4.2% of patients who received combination therapy discontinued treatment because of adverse … However this expert also noted as more targeted therapies with high treatment costs emerge, payers

454. Effective Health Care (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/TND_0094_04-09-2009.pdf
     January 01, 2009 - for autism including occupational, speech, and physical therapies and drug effectiveness. … Areas of interest from the second nominator include combined treatments, effectiveness of early interventions … Understanding the combined effectiveness of medical and behavioral treatments a. … treatment plus a pharmacological treatment versus pharmacological treatment alone in reducing depressive … clear that there is a real need for synthesized research that evaluates the evidence base for various treatments

455. Insulin-Blood-Sugar-2010 Executive (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/insulin-blood-sugar-2010_executive.pdf
     January 01, 2010 - expected to increase to 39 million people by 2050.2-4 Thus, millions of people require glucose-lowering therapies … .14 The role of SMBG is less clear for patients using less frequent insulin injections, noninsulin therapies … and intervention treatments, which may have biased results to the null. … settings or all patients with diabetes mellitus, as the initiation, instruction, monitoring, and therapeutic … Long-acting insulin analogs versus insulin pump therapy for the treatment of type 1 and type 2 diabetes

456. Effective Health Care (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/TND__0355_09-22-2010.pdf
     January 01, 2010 - benzodiazepine receptor agonists, or antidepressants), complementary and alternative care, relaxation therapy … , cognitive behavioral therapy, hormones Comparator(s): Placebo or comparison to another insomnia … Treatment of chronic insomnia is a dilemma commonly encountered in primary care. … medications are most effective and when medications should be used as opposed to nonpharmacologic treatments

457. App-D-Opioid-Chronic-Pain-Surveill-Report-1 (xls file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/app-d-opioid-chronic-pain-surveill-report-1.xlsx
     September 30, 2015 - Pain > 3 months, currently prescribed opioids; excluded cancer and end-of-life treatment A. … Integrated psychosocial group treatment (15) B. Usual care (15) A vs. … : 5% Prior inpatient treatment: 16% Mean current pain level (0-10, 10 high): 7.4 Average pain level ( … group, but the trial did not indicate clear differences between treatments for pain, functioning, depression … , or drug use Harms not reported by treatment group Suspected abuse of study medication (n=2) Sedation

458. Diabetes Mellitus (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/07_diabetes_potential_high_impact_2012-12-10.pdf
     January 01, 2012 - Many patients with T2DM do not meet treatment goals and require additional therapy with one of two … Despite combined hypoglycemic therapy, many patients with T2DM can still fail to meet treatment goals … Both treatments were generally well tolerated. … Despite combined hypoglycemic therapy, many patients with T2DM can still fail to meet treatment goals … ITCA 650 for zero-order continuous delivery of exenatide at therapeutic levels using 3-, 6-, and

459. #05 DEPRESSION (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/05_depression_potential_high_impact_june_2012.pdf
     January 01, 2012 - Food and Drug Administration has not approved any therapies, is being explored. … third-line therapies for MDD, a proportion of patients affected by MDD have treatment-refractory disease … DBS therapy is incompatible with some other device-based depression treatments. … Menlo Park (CA): Corcept Therapeutics; [accessed 2011 Oct 18]. [2 p]. … Menlo Park (CA): Corcept Therapeutics; [accessed 2011 Oct 18]. [2 p].

460. Infectious Disease Including HIV/AIDS #09 (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/infectious-disease-horizon-scan-high-impact-1412.pdf
     December 22, 2014 - market for HCV treatments. … The high cost of emerging HCV therapies combined with the large population of patients requiring treatment … The high cost of emerging HCV therapies combined with the large population of patients requiring treatment … Janssen Therapeutics. … Titusville (NJ): Janssen Therapeutics; 2014 Nov. 44 p.